Biopharmecuticals: Approval Trends in 2006 - Thirteen biopharmaceuticals gained marketing authorization - BioPharm International

ADVERTISEMENT

Biopharmecuticals: Approval Trends in 2006
Thirteen biopharmaceuticals gained marketing authorization


BioPharm International
Volume 21, Issue 9

Clinical data supporting approval was predominantly generated by an open label, multinational randomized trial involving 463 patients. One group was administered the product while the other group received supportive care alone. Administration of Vectibix resulted in prolonged progression-free survival, from an average of 60 days to 96 days. The most common and sometimes severe negative side effects included dermatologic toxicities and adverse (sometimes severe infusion related) reactions also occurred in a minority of recipients. The product is manufactured and marketed by Amgen (Thousand Oaks, CA).

Gary Walsh, PhD, is an associate professor in the Industrial Biochemistry Program at the University of Limerick, Limerick City, Ireland, +353.61.202664,

REFERENCES

1. US Food and Drug Administration. Approvals of FDA-regulated products. Available from http://www.fda.gov/opacom/7approvl.html.

2. European Medicines Agency. EMEA annual report 2006. Available from http:// http://www.emea.europa.eu/index/indexh1.htm.

3. European Medicines Agency. EPARs for authorised medicinal products for human use. Available from http:// http://www.emea.europa.eu/htms/human/epar/eparintro.htm.

4. Walsh G. Biopharmaceuticals: approvals and approval trends in 2004. BioPharm Int. 2005;18(8):58–65.

5. Walsh, G. Biopharmaceuticals: approval trends in 2005. BioPharm Int. 2006;19(8):58–68.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
Author Guidelines
Source: BioPharm International,
Click here